Roche taps Eli Lilly executive as chief medical officer
ZURICH, Aug 19 (Reuters) - Swiss drugmaker Roche Holding ROG.S on Monday named Eli Lilly LLY.N executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.
Garraway, most recently Eli Lilly's senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco.
Horning will retire as of the end of 2019.
(Reporting by John Miller, Writing by Michael Shields. Editing by Jane Merriman)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.